<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>SULINDAC- sulindacÂ tabletÂ </strong><br>Golden State Medical Supply, Inc.<br></p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>**The safety and effectiveness of Sulindac Tablets, USP have not been established in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients who are designated in the American <span class="product-label-link" type="condition" conceptid="138845" conceptname="Rheumatism">Rheumatism</span> Association classification as Functional Class IV (incapacitated, largely or wholly bedridden, or confined to wheelchair, little or no self-care).</dd>
</dl>
</div>
<h1>Sulindac Tablets USP, 150 mg and 200 mg<br>Rx only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_290a4eb9-47c1-4405-af98-5b1f9590cb35"></a><a name="section-1"></a><p></p>
<h1>Boxed Warning</h1>
<p class="First"><span class="Bold">Cardiovascular Risk</span></p>
<ul>
<li>NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (See <a href="#i4i_warnings_id_da2bbcf1-d1e9-4556-a9da-071e1d3445bf">WARNINGS </a>)</li>
<li>SULINDAC is contraindicated for the treatment of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery (See <a href="#i4i_warnings_id_da2bbcf1-d1e9-4556-a9da-071e1d3445bf">WARNINGS </a>).<br>
</li>
</ul>
<p><span class="Bold">Gastrointestinal Risk</span></p>
<ul><li>NSAIDs cause an increased risk of serious gastrointestinal adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (See <a href="#i4i_warnings_id_da2bbcf1-d1e9-4556-a9da-071e1d3445bf">WARNINGS </a>).</li></ul>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_41c789ce-59e6-4c3a-8919-b4f5b7507cf2"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Sulindac is a non-steroidal, anti-inflammatory indene derivative designated chemically as (Z)-5-fluoro-2-methyl-1-[[Ï?-(methylsulfinyl)phenyl]methylene]-1<span class="Italics">H</span>-indene-3-acetic acid. It is not a salicylate, pyrazolone or propionic acid derivative. Its empirical formula is C<span class="Sub">20</span>H<span class="Sub">17</span>FO<span class="Sub">3</span>S, with a molecular weight of 356.42. </p>
<p><img alt="Chemical Structure - Sulindac" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=19dde540-3d29-4db4-9570-6ca15f09e0fe&amp;name=19dde540-3d29-4db4-9570-6ca15f09e0fe-03.jpg">         Sulindac, a yellow crystalline compound, is a weak organic acid practically insoluble in water below pH 4.5, but very soluble as the sodium salt or in buffers of pH 6 or higher.</p>
<p>Sulindac is available in 150 and 200 mg tablets for oral administration. Each tablet contains the following inactive ingredients: magnesium stearate, microcrystalline cellulose, plasdone and sodium starch glycolate.</p>
<p>Following absorption, sulindac undergoes two major biotransformations - reversible reduction to the sulfide metabolite, and irreversible oxidation to the sulfone metabolite. Available evidence indicates that the biological activity resides with the sulfide metabolite.</p>
<p>The structural formulas of sulindac and its metabolites are:</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_a18a5ad6-02a3-40cb-9a51-8753441f302e"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_696e294d-88fd-44cd-b533-b7bb148b1491"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">Sulindac is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic activities in animal models. The mechanism of action, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_1a35e04f-5381-4694-ae01-8e43409ebb5c"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_05705575-cb51-4293-b05b-b599aaba3d06"></a><a name="section-2.3"></a><p></p>
<h2><span class="Italics"><span class="Bold">Absorption</span></span></h2>
<p class="First">The extent of sulindac absorption from Sulindac Tablets, USP is similar as compared to sulindac solution.</p>
<p>There is no information regarding food effect on sulindac absorption. Antacids containing magnesium hydroxide 200 mg and aluminum hydroxide 225 mg per 5 mL have been shown not to significantly decrease the extent of sulindac absorption.</p>
<a name="id_b733d9a2-18f1-427e-9327-0ade7d68d482"></a><table border="single" width="443.000">
<caption><span>Pharmacokinetic Parameters</span></caption>
<col width="36.8%">
<col width="28.9%">
<col width="34.3%">
<tfoot><tr class="Last"><td class="Botrule Lrule Rrule" align="left" colspan="3" valign="top">Pharmacokinetic Parameters for Normal and Healthy Patients</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="justify" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">TABLE 1</span></td>
<td class="Botrule Rrule" align="justify" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="justify" valign="top">
<p class="First"><span class="Bold">PHARMACOKINETIC</span></p>
<span class="Bold">PARAMETERS</span>
</td>
<td class="Botrule Rrule" align="justify" valign="top"><span class="Bold">NORMAL</span></td>
<td class="Botrule Rrule" align="justify" valign="top"><span class="Bold">ELDERLY</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="justify" valign="top">Tmax</td>
<td class="Botrule Rrule" align="justify" valign="top">
<p class="First">Age 19-41 (n=24)</p>
<p>(200 mg tablet)</p>
<p>3.38 Â± 2.30 S</p>
<p>4.88 Â± 2.57 SP</p>
<p>4.96 Â± 2.36 SF</p>
<p>(150 mg tablet)</p>
<p>3.90 Â± 2.30 S</p>
<p>5.85 Â± 4.49 SP</p>6.15 Â± 3.07 SF</td>
<td class="Botrule Rrule" align="justify" valign="top">
<p class="First">Age 65-87 (n=12) 400 mg qd</p>
<p>2.54 Â± 1.52 S</p>
<p>5.75 Â± 2.81 SF</p>6.83 Â± 4.19 SP </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="justify" valign="top">Renal Clearance</td>
<td class="Botrule Rrule" align="justify" valign="top">
<p class="First">(200 mg tablet)</p>
<p>68.12 Â± 27.56 mL/min S</p>
<p>36.58 Â± 12.61 mL/min SP</p>
<p>(150 mg tablet)</p>
<p>74.39 Â± 34.15 mL/min S</p>41.75 Â± 13.72 mL/min SP</td>
<td class="Botrule Rrule" align="justify" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="justify" valign="top">Mean effective Half life (h)</td>
<td class="Botrule Rrule" align="justify" valign="top">
<p class="First">7.8 S</p>16.4 SF</td>
<td class="Botrule Rrule" align="justify" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="justify" valign="top"></td>
<td class="Rrule" align="justify" valign="top">
<p class="First"><span class="Bold">S = Sulindac</span></p>
<p><span class="Bold">SF = Sulindac Sulfide</span></p>
<span class="Bold">SP = Sulindac Sulfone</span>
</td>
<td class="Botrule Rrule" align="justify" valign="top"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_71501eb6-c9a4-4690-95be-70e852f84bcc"></a><a name="section-2.4"></a><p></p>
<h2><span class="Bold"><span class="Italics">Distribution</span></span></h2>
<p class="First">Sulindac, and its sulfone and sulfide metabolites, are 93.1, 95.4, and 97.9% bound to plasma proteins, predominantly to albumin. Plasma protein binding measured over a concentration range (0.5-2.0 Âµg/mL) was constant. Following an oral, radiolabeled dose of sulindac in rats, concentrations of radiolabel in red blood cells were about 10% of those in plasma. Sulindac penetrates the blood-brain and placental barriers. Concentrations in brain did not exceed 4% of those in plasma. Plasma concentrations in the placenta and in the fetus were less than 25% and 5% respectively, of systemic plasma concentrations. Sulindac is excreted in rat milk; concentrations in milk were 10 to 20% of those levels in plasma. It is not known if sulindac is excreted in human milk.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_5ce5bf0a-9eb8-4c58-8fee-22bc0e610fc4"></a><a name="section-2.5"></a><p></p>
<h2><span class="Italics"><span class="Bold">Metabolism</span></span></h2>
<p class="First">Sulindac undergoes two major biotransformations of its sulfoxide moiety: oxidation to the inactive sulfone and reduction to the pharmacologically active sulfide. The latter is readily reversible in animals and in man. These metabolites are present as unchanged compounds in plasma and principally as glucuronide conjugates in human urine and bile. A dihydroxydihydro analog has also been identified as a minor metabolite in human urine.</p>
<p>With the twice-a-day dosage regimen, plasma concentrations of sulindac and its two metabolites accumulate: mean concentration over a dosage interval at steady state relative to the first dose averages 1.5 and 2.5 times higher, respectively, for sulindac and its active sulfide metabolite.</p>
<p>Sulindac and its sulfone metabolite undergo extensive enterohepatic circulation relative to the sulfide metabolite in animals. Studies in man have also demonstrated that recirculation of the parent drug sulindac and its sulfone metabolite is more extensive than that of the active sulfide metabolite. The active sulfide metabolite accounts for less than six percent of the total intestinal exposure to sulindac and its metabolites.</p>
<p>Biochemical as well as pharmacological evidence indicates that the activity of sulindac resides in its sulfide metabolite. An <span class="Italics">in-vitro</span> assay for inhibition of cyclooxygenase activity exhibited an EC<span class="Sub">50</span> of 0.02ÂµM for sulindac sulfide. <span class="Italics">In-vivo</span> models of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> indicate that activity is more highly correlated with concentrations of the metabolite than with parent drug concentrations.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_dc7537b7-82fb-4134-94af-6cf29f4d2096"></a><a name="section-2.6"></a><p></p>
<h2>Elimination</h2>
<p class="First">Approximately 50% of the administered dose of sulindac is excreted in the urine with the conjugated sulfone metabolite accounting for the major portion. Less than 1% of the administered dose of sulindac appears in the urine as the sulfide metabolite. Approximately 25% is found in the feces, primarily as the sulfone and sulfide metabolites.</p>
<p>The mean effective half life (T<span class="Sub">1/2</span>) is 7.8 and 16.4 hours, respectively, for sulindac and its active sulfide metabolite.</p>
<p>Because sulindac is excreted in the urine primarily as biologically inactive forms, it may possibly affect renal function to a lesser extent than other non-steroidal anti-inflammatory drugs; however, renal adverse experiences have been reported with sulindac (see <span class="Bold"><a href="#i4i_adverse_effects_id_86bd9b1b-ebbe-41c8-ade4-6a1d410dcabd">ADVERSE REACTIONS</a></span>).</p>
<p>In a study of patients with chronic glomerular disease treated with therapeutic doses of sulindac, no effect was demonstrated on renal blood flow, glomerular filtration rate, or urinary excretion of prostaglandin E<span class="Sub">2</span> and the primary metabolite of prostacyclin, 6-keto-PGF<span class="Sub">1Î±</span>. However, in other studies in healthy volunteers and patients with liver disease, sulindac was found to blunt the renal responses to intravenous furosemide, i.e., the <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, natriuresis, increments in plasma renin activity and urinary excretion of prostaglandins. These observations may represent a differentiation of the effects of sulindac on renal functions based on differences in pathogenesis of the renal prostaglandin <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> associated with differing dose-response relationships of different NSAIDs to the various renal functions influenced by prostaglandins (see <span class="Bold"><a href="#i4i_precautions_id_57fd4ab8-65d0-4137-bf04-3cefd37bde03">PRECAUTIONS</a></span>).</p>
<p>In healthy men, the average fecal blood loss, measured over a two-week period during administration of 400 mg per day of sulindac, was similar to that for placebo, and was statistically significantly less than that resulting from 4800 mg per day of aspirin.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_1f949283-7302-468e-9cc1-83020274625c"></a><a name="section-2.7"></a><p></p>
<h2>Distribution</h2>
<p class="First">Sulindac, and its sulfone and sulfide metabolites, are 93.1, 95.4, and 97.9% bound to plasma proteins, predominantly to albumin. Plasma protein binding measured over a concentration range (0.5-2.0 Âµg/mL) was constant. Following an oral, radiolabeled dose of sulindac in rats, concentrations of radiolabel in red blood cells were about 10% of those in plasma. Sulindac penetrates the blood-brain and placental barriers. Concentrations in brain did not exceed 4% of those in plasma. Plasma concentrations in the placenta and in the fetus were less than 25% and 5% respectively, of systemic plasma concentrations. Sulindac is excreted in rat milk; concentrations in milk were 10 to 20% of those levels in plasma. It is not known if sulindac is excreted in human milk.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_39821139-eb1b-4928-ba6c-0cab9c9e8c01"></a><a name="section-2.8"></a><p></p>
<h2><span class="Bold"><span class="Italics">Metabolism</span></span></h2>
<p class="First">Sulindac undergoes two major biotransformations of its sulfoxide moiety: oxidation to the inactive sulfone and reduction to the pharmacologically active sulfide. The latter is readily reversible in animals and in man. These metabolites are present as unchanged compounds in plasma and principally as glucuronide conjugates in human urine and bile. A dihydroxydihydro analog has also been identified as a minor metabolite in human urine.</p>
<p>With the twice-a-day dosage regimen, plasma concentrations of sulindac and its two metabolites accumulate: mean concentration over a dosage interval at steady state relative to the first dose averages 1.5 and 2.5 times higher, respectively, for sulindac and its active sulfide metabolite.</p>
<p>Sulindac and its sulfone metabolite undergo extensive enterohepatic circulation relative to the sulfide metabolite in animals. Studies in man have also demonstrated that recirculation of the parent drug sulindac and its sulfone metabolite is more extensive than that of the active sulfide metabolite. The active sulfide metabolite accounts for less than six percent of the total intestinal exposure to sulindac and its metabolites.</p>
<p>Biochemical as well as pharmacological evidence indicates that the activity of sulindac resides in its sulfide metabolite. An <span class="Italics">in-vitro</span> assay for inhibition of cyclooxygenase activity exhibited an EC<span class="Sub">50</span> of 0.02ÂµM for sulindac sulfide. <span class="Italics">In-vivo</span> models of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> indicate that activity is more highly correlated with concentrations of the metabolite than with parent drug concentrations.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_ebe0edbc-5a2f-4dfd-9570-6bde9ef1d536"></a><a name="section-2.9"></a><p></p>
<h2>Elimination</h2>
<p class="First">Approximately 50% of the administered dose of sulindac is excreted in the urine with the conjugated sulfone metabolite accounting for the major portion. Less than 1% of the administered dose of sulindac appears in the urine as the sulfide metabolite. Approximately 25% is found in the feces, primarily as the sulfone and sulfide metabolites.</p>
<p>The mean effective half life (T<span class="Sub">1/2</span>) is 7.8 and 16.4 hours, respectively, for sulindac and its active sulfide metabolite.</p>
<p>Because sulindac is excreted in the urine primarily as biologically inactive forms, it may possibly affect renal function to a lesser extent than other non-steroidal anti-inflammatory drugs; however, renal adverse experiences have been reported with sulindac (see <a href="#i4i_adverse_effects_id_86bd9b1b-ebbe-41c8-ade4-6a1d410dcabd">ADVERSE REACTIONS</a>).</p>
<p>In a study of patients with chronic glomerular disease treated with therapeutic doses of sulindac, no effect was demonstrated on renal blood flow, glomerular filtration rate, or urinary excretion of prostaglandin E<span class="Sub">2</span> and the primary metabolite of prostacyclin, 6-keto-PGF<span class="Sub">1Î±</span>. However, in other studies in healthy volunteers and patients with liver disease, sulindac was found to blunt the renal responses to intravenous furosemide, i.e., the <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, natriuresis, increments in plasma renin activity and urinary excretion of prostaglandins. These observations may represent a differentiation of the effects of sulindac on renal functions based on differences in pathogenesis of the renal prostaglandin <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> associated with differing dose-response relationships of different NSAIDs to the various renal functions influenced by prostaglandins (see <a href="#i4i_precautions_id_57fd4ab8-65d0-4137-bf04-3cefd37bde03">PRECAUTIONS</a>).</p>
<p>In healthy men, the average fecal blood loss, measured over a two-week period during administration of 400 mg per day of sulindac, was similar to that for placebo, and was statistically significantly less than that resulting from 4800 mg per day of aspirin.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_0b877d24-56cf-437a-b326-16f9873fb8c2"></a><a name="section-2.10"></a><p></p>
<h2>Special Populations</h2>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_d3b41eaf-98f5-40d2-867c-95af2d909cb6"></a><a name="section-2.11"></a><p></p>
<h2>Pediatrics</h2>
<p class="First">The pharmacokinetics of sulindac have not been investigated in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_aa62ac4e-000d-4061-99c7-36fb83fd6d92"></a><a name="section-2.12"></a><p></p>
<h2>Race</h2>
<p class="First">Pharmacokinetic differences due to race have not been identified.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_3f167eae-cd4f-454e-b6d9-9bf0873f43d8"></a><a name="section-2.13"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">Patients with acute and chronic <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> may require reduced doses of sulindac compared to patients with normal hepatic function since hepatic metabolism is an important elimination pathway.</p>
<p>Following a single dose, plasma concentrations of the active sulfide metabolite have been reported to be higher in patients with <span class="product-label-link" type="condition" conceptid="201612" conceptname="Alcoholic liver damage">alcoholic liver disease</span> compared to healthy normal subjects.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_dd879cc6-0616-4b2a-a059-a6309811ad88"></a><a name="section-2.14"></a><p></p>
<h2><span class="Italics"><span class="Bold"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span></span></h2>
<p class="First">Sulindac pharmacokinetics have been investigated in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. The disposition of sulindac was studied in end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> patients requiring hemodialysis. Plasma concentrations of sulindac and its sulfone metabolite were comparable to those of normal healthy volunteers whereas concentrations of the active sulfide metabolite were significantly reduced. Plasma protein binding was reduced and the AUC of the unbound sulfide metabolite was about half that in healthy subjects.</p>
<p>Sulindac and its metabolites are not significantly removed from the blood in patients undergoing hemodialysis.</p>
<p>Since sulindac is eliminated primarily by the kidneys, patients with significantly <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> should be closely monitored.</p>
<p> A lower daily dosage should be anticipated to avoid excessive drug accumulation.</p>
<p>In controlled clinical studies sulindac was evaluated in the following five conditions:</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_5fb81740-4a47-4443-9bcb-fdf071699361"></a><a name="section-2.15"></a><p></p>
<h2><span class="Italics"><span class="Bold">1. <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span></span></span></h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of the hip and knee, the anti-inflammatory and analgesic activity of sulindac was demonstrated by clinical measurements that included: assessments by both patient and investigator of overall response; decrease in disease activity as assessed by both patient and investigator; improvement in ARA Functional Class; relief of night <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>; improvement in overall evaluation of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, including <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on weight bearing and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on active and passive motion; improvement in joint mobility, range of motion, and functional activities; decreased <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>; and decreased duration of <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span> following prolonged inactivity.</p>
<p>In clinical studies in which dosages were adjusted according to patient needs, Sulindac Tablets, 200 to 400 mg daily was shown to be comparable in effectiveness to aspirin 2400 to 4800 mg daily. Sulindac Tablets were generally well tolerated, and patients on it had a lower overall incidence of total adverse effects, of milder gastrointestinal reactions, and of <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> than did patients on aspirin. <span class="Bold">(See <a href="#i4i_adverse_effects_id_86bd9b1b-ebbe-41c8-ade4-6a1d410dcabd">ADVERSE REACTIONS</a>)</span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_9515ef52-92c7-41d6-af3d-7f30f3c02df8"></a><a name="section-2.16"></a><p></p>
<h2><span class="Bold"><span class="Italics">2. <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></span></span></h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, the anti-inflammatory and analgesic activity of sulindac was demonstrated by clinical measurements that included: assessments by both patient and investigator of overall response; decrease in disease activity as assessed by both patient and investigator; reduction in overall <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>; reduction in duration and severity of morning <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>; reduction in day and night <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>; decrease in time required to walk 50 feet; decrease in general <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> as measured on a visual analog scale; improvement in the Ritchie articular index; decrease in proximal interphalangeal joint size; improvement in ARA Functional Class; increase in grip strength; reduction in painful joint count and score; reduction in <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">swollen joint</span> count and score; and increased flexion and extension of the wrist.</p>
<p>In clinical studies in which dosages were adjusted according to patient needs, sulindac 300 to 400 mg daily was shown to be comparable in effectiveness to aspirin 3600 to 4800 mg daily. Sulindac was generally well tolerated, and patients on it had a lower overall incidence of total adverse effects, of milder gastrointestinal reactions, and of <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> than did patients on aspirin. (See <span class="Bold"><a href="#i4i_adverse_effects_id_86bd9b1b-ebbe-41c8-ade4-6a1d410dcabd">ADVERSE REACTIONS</a></span>.)</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, sulindac may be used in combination with gold salts at usual dosage levels. In clinical studies, sulindac added to the regimen of gold salts usually resulted in additional symptomatic relief but did not alter the course of the underlying disease.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_9dc011c4-d12e-4b27-a545-13235eb02d7d"></a><a name="section-2.17"></a><p></p>
<h2><span class="Bold"><span class="Italics">3. <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">Ankylosing Spondylitis</span></span></span></h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span>, the anti-inflammatory and analgesic activity of sulindac was demonstrated by clinical measurements that included: assessments by both patient and investigator of overall response; decrease in disease activity as assessed by both patient and investigator; improvement in ARA Functional Class; improvement in patient and investigator evaluation of spinal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> and/or spasm; reduction in the duration of morning <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>; increase in the time to onset of <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>; relief of night <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>; increase in chest expansion; and increase in spinal mobility evaluated by fingers-to-floor distance, occiput to wall distance, the Schober Test, and the Wright Modification of the Schober Test. In a clinical study in which dosages were adjusted according to patient need, Sulindac 200 to 400 mg daily was as effective as Indomethacin 75 to 150 mg daily. In a second study, Sulindac 300 to 400 mg daily was comparable in effectiveness to phenylbutazone 400 to 600 mg daily. Sulindac was better tolerated than phenylbutazone. (See <span class="Bold"><a href="#i4i_adverse_effects_id_86bd9b1b-ebbe-41c8-ade4-6a1d410dcabd">ADVERSE REACTIONS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_4bf7f645-1dfd-415c-a62d-75287ad0158a"></a><a name="section-2.18"></a><p></p>
<h2><span class="Italics">4. <span class="Bold">Acute Painful Shoulder (Acute subacromial <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span>/supra2spinatus <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span></span></span></h2>
<p class="First">In patients with acute painful shoulder (acute subacromial <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span>/supraspinatus <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span>), the anti-inflammatory and analgesic activity of sulindac was demonstrated by clinical measurements that included: assessments by both patient and investigator of overall response; relief of night <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, spontaneous <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on active motion; decrease in local <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>; and improvement in range of motion measured by abduction, and internal and external rotation. In clinical studies in acute painful shoulder, sulindac 300 to 400 mg daily and oxyphenbutazone 400 to 600 mg daily were shown to be equally effective and well tolerated.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_98a669a2-e627-473b-abdf-bff1c024c111"></a><a name="section-2.19"></a><p></p>
<h2><span class="Italics">5. <span class="Bold">Acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span></span></span></h2>
<p class="First">In patients with acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span>, the anti-inflammatory and analgesic activity of sulindac was demonstrated by clinical measurements that included: assessments by both the patient and investigator of overall response; relief of weight-bearing <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>; relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at rest and on active and passive motion; decrease in <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>; reduction in warmth and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>; increase in range of motion; and improvement in ability to function. In clinical studies, sulindac at 400 mg daily and phenylbutazone at 600 mg daily were shown to be equally effective. In these short-term studies in which reduction of dosage was permitted according to response, both drugs were equally well tolerated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_b5b4e817-462e-4924-a283-67fe7d89b79b"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <a href="#i4i_warnings_id_da2bbcf1-d1e9-4556-a9da-071e1d3445bf">WARNINGS </a>).</p>
<p>Sulindac is indicated for acute or long-term use in the relief of signs and symptoms of the following:</p>
<p>1. <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span></p>
<p>2. <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid arthritis</span>**</p>
<p>3. <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">Ankylosing spondylitis</span></p>
<p>4. Acute painful shoulder (Acute subacromial <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span>/supraspinatus <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span>)</p>
<p>5. Acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_b933ee67-08c8-4a98-8579-23cf3c60dee0"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Sulindac is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to sulindac or the excipients (see <span class="Bold">DESCRIPTION</span>).</p>
<p>Sulindac should not be given to patients who have experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> to NSAIDs have been reported in such patients (see<a href="#i4i_warnings_id_da2bbcf1-d1e9-4556-a9da-071e1d3445bf">WARNINGS </a> - <a href="#i4i_warnings_id_be28849f-c365-4a6b-b074-41f877befb18">Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> </a> and <a href="#i4i_precautions_id_57fd4ab8-65d0-4137-bf04-3cefd37bde03">PRECAUTIONS</a> - <a href="#i4i_precautions_id_9d624b11-e7dc-4ccc-b7ee-f7068a8412bf">Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> </a>).</p>
<p>Sulindac is contraindicated for the treatment of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery (see <a href="#i4i_warnings_id_da2bbcf1-d1e9-4556-a9da-071e1d3445bf">WARNINGS </a>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_da2bbcf1-d1e9-4556-a9da-071e1d3445bf"></a><a name="section-5"></a><p></p>
<h1>WARNINGS<a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a>
</h1>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_b60cf391-258e-4119-96e1-203245c5c4ee"></a><a name="section-5.1"></a><p></p>
<h2><span class="Bold"><span class="Italics">CARDIOVASCULAR EFFECTS</span></span></h2>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_6b0ca612-6bfc-42ca-9764-30f04b35c524"></a><a name="section-5.2"></a><p></p>
<h2><span class="Italics">Cardiovascular Thrombotic Events</span></h2>
<p class="First">Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, the lowest effective dose should be used for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Patients should be informed about the signs and/or symptoms of serious CV events and the steps to take if they occur.</p>
<p>There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID does increase the risk of serious GI events (see <a href="#i4i_warnings_id_8d0c8416-06f8-44d7-85b5-71a598e004b4">GI </a><span class="Bold"><a href="#i4i_warnings_id_da2bbcf1-d1e9-4556-a9da-071e1d3445bf">WARNINGS </a></span>).</p>
<p>Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the first 10-14 days following CABG surgery found an increased incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (see <a href="#i4i_contraindications_id_b933ee67-08c8-4a98-8579-23cf3c60dee0">CONTRAINDICATIONS</a>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_1fb7b16c-41a0-444c-b703-523ea3a5aaf9"></a><a name="section-5.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">NSAIDs, including sulindac, can lead to onset of new <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or worsening of pre-existing <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including sulindac, should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_f5f7c68a-df6b-45e0-b5f5-f575a032fa0c"></a><a name="section-5.4"></a><p></p>
<h2><span class="Italics"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been observed in some patients taking NSAIDs. Sulindac should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_8d0c8416-06f8-44d7-85b5-71a598e004b4"></a><a name="section-5.5"></a><p></p>
<h2><span class="Italics">Gastrointestinal Effects - Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</span></h2>
<p class="First">NSAIDs, including sulindac, can cause serious gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy, is symptomatic. Upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk.</p>
<p>NSAIDs should be prescribed with extreme caution in those with prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. Patients with a <span class="Italics">prior history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> and/or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span></span> who use NSAIDs have a greater than 10-fold increased risk for developing a <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI bleed</span> compared to patients with neither of these risk factors. Other factors that increase the risk for GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore, special care should be taken in treating this population.</p>
<p>To minimize the potential risk for an adverse GI event in patients treated with an NSAID, the lowest effective dose should be used for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected. This should include discontinuation of the NSAID until a serious GI adverse event is ruled out. For high risk patients, alternate therapies that do not involve NSAIDs should be considered.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_6812b4af-ea85-40e6-8b94-f7638b7eb92d"></a><a name="section-5.6"></a><p></p>
<h2>
<span class="Italics">Hepatic Effect</span><span class="Italics">s</span>
</h2>
<p class="First">In addition to <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> involving the liver, in some patients the findings are consistent with those of <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span> (see <a href="#i4i_warnings_id_da2bbcf1-d1e9-4556-a9da-071e1d3445bf">WARNINGS </a>). As with other non-steroidal anti-inflammatory drugs, borderline elevations of one or more liver tests without any other signs and symptoms may occur in up to 15% of patients taking NSAIDs including sulindac. These laboratory abnormalities may progress, may remain essentially unchanged, or may be transient with continued therapy. The SGPT (ALT) test is probably the most sensitive indicator of liver dysfunction. Meaningful (3 times the upper limit of normal) elevations of SGPT or <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> (AST) occurred in controlled clinical trials in less than 1% of patients. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and fatal fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, some of them with fatal outcomes have been reported.</p>
<p>A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with sulindac. Although such reactions as described above are rare, if abnormal liver tests persist or worsen, if clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.), sulindac should be discontinued.</p>
<p>In clinical trials with sulindac, the use of doses of 600 mg/day has been associated with an increased incidence of mild liver test abnormalities (see <a href="#i4i_dosage_admin_id_53f5a12c-cc0b-4b7e-acff-128b74b93c3a">DOSAGE AND ADMINISTRATION</a>for maximum dosage recommendation).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_bff5d5d1-6e9a-4e1f-957a-c2d42393e6f4"></a><a name="section-5.7"></a><p></p>
<h2>Renal Effects</h2>
<p class="First">Long-term administration of NSAIDs has resulted in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a non-steroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, those taking diuretics and ACE inhibitors, patients who are volume-depleted, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_1c232346-c8a8-4fcf-84e6-04b7bc606faa"></a><a name="section-5.8"></a><p></p>
<h2>Advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></h2>
<p class="First">No information is available from controlled clinical studies regarding the use of sulindac in patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Therefore, treatment with sulindac is not recommended in these patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. If sulindac therapy must be initiated, close monitoring of the patientâs renal function is advisable.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_be28849f-c365-4a6b-b074-41f877befb18"></a><a name="section-5.9"></a><p></p>
<h2><span class="Italics">Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></span></h2>
<p class="First">As with other NSAIDs, anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> may occur in patients without known prior exposure to sulindac. Sulindac should not be given to patients with the aspirin triad. This symptom complex typically occurs in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients who experience <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>, or who exhibit severe, potentially fatal <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> after taking aspirin or other NSAIDs (see <a href="#i4i_contraindications_id_b933ee67-08c8-4a98-8579-23cf3c60dee0">CONTRAINDICATIONS</a> and <span class="Bold"><a href="#i4i_precautions_id_9d624b11-e7dc-4ccc-b7ee-f7068a8412bf">PRECAUTIONSâ Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>)</a></span>. Emergency help should be sought in cases where an anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_12263461-b1ef-4955-969c-fd9ce7b7f64f"></a><a name="section-5.10"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">NSAIDs, including sulindac, can cause serious adverse events such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_f308dd91-9c21-4a1f-80a6-3dc861d09341"></a><a name="section-5.11"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Rarely, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and other evidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (see <a href="#i4i_adverse_effects_id_86bd9b1b-ebbe-41c8-ade4-6a1d410dcabd">ADVERSE REACTIONS</a>) including abnormalities in one or more liver function tests and severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> have occurred during therapy with sulindac. Fatalities have occurred in these patients. <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, or both, with or without <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, may occur usually within the first one to three months of therapy. Determinations of liver function should be considered whenever a patient on therapy with sulindac develops unexplained <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other dermatologic reactions or constitutional symptoms. If unexplained <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other evidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> occurs, therapy with sulindac should be discontinued. The elevated temperature and abnormalities in liver function caused by sulindac characteristically have reverted to normal after discontinuation of therapy. Administration of sulindac should not be reinstituted in such patients.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_78b7aadb-9f8a-49c2-ba71-eba8492a1de0"></a><a name="section-5.12"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">In late pregnancy, as with other NSAIDs, sulindac should be avoided because it may cause premature closure of the ductus arteriosus.</p>
</div>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>**The safety and effectiveness of Sulindac Tablets, USP have not been established in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients who are designated in the American <span class="product-label-link" type="condition" conceptid="138845" conceptname="Rheumatism">Rheumatism</span> Association classification as Functional Class IV (incapacitated, largely or wholly bedridden, or confined to wheelchair, little or no self-care).</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_57fd4ab8-65d0-4137-bf04-3cefd37bde03"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_bae4b13d-1e7f-4a37-b1d0-6b5b86961771"></a><a name="section-6.1"></a><p></p>
<h2><span class="Italics">General</span></h2>
<p class="First">Sulindac cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.</p>
<p>The pharmacological activity of sulindac in reducing <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_0049db22-9402-4a39-ba04-b29fa5eaf7db"></a><a name="section-6.2"></a><p></p>
<h2><span class="Italics">Hematological Effects</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> is sometimes seen in patients receiving NSAIDs, including sulindac. This may be due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including sulindac, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
<p>NSAIDs inhibit platelet aggregation and have been shown to prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving sulindac who may be adversely affected by alterations in platelet function, such as those with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span> or patients receiving anticoagulants, should be carefully monitored.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_9d624b11-e7dc-4ccc-b7ee-f7068a8412bf"></a><a name="section-6.3"></a><p></p>
<h2><span class="Italics">Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> may have aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The use of aspirin in patients with aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been associated with severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> which can be fatal. Since cross reactivity, including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, between aspirin and other non-steroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, sulindac should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_db28b787-d854-44c5-86e1-8b32f4675141"></a><a name="section-6.4"></a><p></p>
<h2><span class="Italics"><span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Renal Calculi</span></span></h2>
<p class="First">Sulindac metabolites have been reported rarely as the major or a minor component in <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal stones</span> in association with other calculus components. Sulindac should be used with caution in patients with a history of renal lithiasis, and they should be kept well hydrated while receiving sulindac.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_fa7b925e-fe0d-4d81-9734-e43ba42d1f45"></a><a name="section-6.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> has been reported in patients receiving sulindac (see <a href="#i4i_adverse_effects_id_86bd9b1b-ebbe-41c8-ade4-6a1d410dcabd">ADVERSE REACTIONS</a>). Should <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> be suspected, the drug should be discontinued and not restarted, supportive medical therapy instituted, and the patient monitored closely with appropriate laboratory studies (e.g., serum and urine amylase, amylase/creatinine clearance ratio, electrolytes, serum calcium, glucose, lipase, etc.). A search for other causes of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> as well as those conditions which mimic <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> should be conducted.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_1cda3a1d-8f6c-4e0e-8293-e432f9a71aac"></a><a name="section-6.6"></a><p></p>
<h2><span class="Italics">Ocular Effects</span></h2>
<p class="First">Because of reports of adverse eye findings with non-steroidal anti-inflammatory agents, it is recommended that patients who develop eye complaints during treatment with sulindac have ophthalmologic studies.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_f51126bc-eb16-47a1-86eb-9bdb2cea8c51"></a><a name="section-6.7"></a><p></p>
<h2><span class="Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></h2>
<p class="First">In patients with poor liver function, delayed, elevated and prolonged circulating levels of the sulfide and sulfone metabolites may occur. Such patients should be monitored closely; a reduction of daily dosage may be required.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_7e74692e-49e4-474d-930f-1bcff834d9c4"></a><a name="section-6.8"></a><p></p>
<h2><span class="Italics">SLE and <span class="product-label-link" type="condition" conceptid="4134867" conceptname="Mixed collagen vascular disease">Mixed Connective Tissue Disease</span></span></h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> (SLE) and <span class="product-label-link" type="condition" conceptid="4134867" conceptname="Mixed collagen vascular disease">mixed connective tissue disease</span>, there may be an increased risk of <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span> (see <a href="#i4i_adverse_effects_id_86bd9b1b-ebbe-41c8-ade4-6a1d410dcabd">ADVERSE REACTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_4dee8219-6ceb-4d9b-a039-1f354dc9a77e"></a><a name="section-6.9"></a><p></p>
<h2><span class="Italics">Information for Patients</span></h2>
<p class="First"><span class="Bold">Patients should be informed of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy. Patients should also be encouraged to read the NSAID Medication Guide that accompanies each prescription dispensed.</span></p>
<ol>
<li>Sulindac, like other NSAIDs, may cause serious CV side effects, such as MI or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious CV events can occur without warning symptoms, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, slurring of speech, and should ask for medical advice when observing any indicative sign or symptoms. Patients should be apprised of the importance of this follow-up (see <a href="#i4i_warnings_id_da2bbcf1-d1e9-4556-a9da-071e1d3445bf">WARNINGS </a> - <a href="#i4i_warnings_id_b60cf391-258e-4119-96e1-203245c5c4ee">CARDIOVASCULAR EFFECTS  </a>).</li>
<li>Sulindac, like other NSAIDs, can cause GI <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and, rarely, serious GI side effects, such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and should ask for medical advice when observing any indicative sign or symptoms including <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, and <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>. Patients should be apprised of the importance of this follow-up (see <a href="#i4i_warnings_id_da2bbcf1-d1e9-4556-a9da-071e1d3445bf">WARNINGS </a> - <a href="#i4i_warnings_id_8d0c8416-06f8-44d7-85b5-71a598e004b4">Gastrointestinal Effects - Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation </a>).</li>
<li>Sulindac, like other NSAIDs, can cause serious skin side effects such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, SJS, and TEN, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may occur without warning, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or other signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> such as <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and should ask for medical advice when observing any indicative signs or symptoms. Patients should be advised to stop the drug immediately if they develop any type of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and contact their physicians as soon as possible.</li>
<li>Patients should promptly report signs or symptoms of unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> to their physicians.</li>
<li>Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and âflu-likeâ? symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy.</li>
<li>Patients should be informed of the signs of an anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat). If these occur, patients should be instructed to seek immediate emergency help (see <span class="Bold"><a href="#i4i_warnings_id_da2bbcf1-d1e9-4556-a9da-071e1d3445bf">WARNINGS </a></span>).</li>
<li>In late pregnancy, as with other NSAIDs, sulindac should be avoided because it may cause premature closure of the ductus arteriosus.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_3883d439-d571-43a4-8177-e6ae19fcb93a"></a><a name="section-6.10"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Because serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, physicians should monitor for signs or symptoms of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients on long-term treatment with NSAIDs should have their CBC and a chemistry profile checked periodically. If clinical signs and symptoms consistent with liver or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> develop, systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.) or if abnormal liver tests persist or worsen, sulindac should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_9688e3df-b47a-4a30-b87d-576874007207"></a><a name="section-6.11"></a><p></p>
<h2>Drug Interactions</h2>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_fbf05030-29db-4094-84e2-9ecf4c874da1"></a><a name="section-6.12"></a><p></p>
<h2><span class="Italics">Ace Inhibitors and Angiotensin II Antagonists</span></h2>
<p class="First">Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors and angiotensin II antagonists. These interactions should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors or angiotensin II antagonists. In some patients with compromised renal function (e.g. elderly patients or patients who are volume-depleted, including those on diuretic therapy) who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of an NSAID and an ACE-inhibitor or an angiotensin II antagonist may result in further deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, which is usually reversible. Therefore, the combination should be administered with caution in patients with compromised renal function.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_2beee214-27e9-4d85-b215-3b03da38b7b4"></a><a name="section-6.13"></a><p></p>
<h2><span class="Italics">Acetaminophen</span></h2>
<p class="First">Acetaminophen had no effect on the plasma levels of sulindac or its sulfide metabolite.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_1d0b1085-f0ab-4f18-9605-dff3cac5cf3c"></a><a name="section-6.14"></a><p></p>
<h2><span class="Italics">Aspirin</span></h2>
<p class="First">The concomitant administration of aspirin with sulindac significantly depressed the plasma levels of the active sulfide metabolite. A double-blind study compared the safety and efficacy of sulindac 300 or 400 mg daily given alone or with aspirin 2.4 g/day for the treatment of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>. The addition of aspirin did not alter the types of clinical or laboratory adverse experiences for sulindac; however, the combination showed an increase in the incidence of gastrointestinal adverse experiences. Since the addition of aspirin did not have a favorable effect on the therapeutic response to sulindac, the combination is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_e0c278f7-ef5b-43cc-a57d-26ea2d3a9549"></a><a name="section-6.15"></a><p></p>
<h2><span class="Italics">Cyclosporine</span></h2>
<p class="First">Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin. NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_d464c770-4ac1-49c1-ace7-0a8480ee05cb"></a><a name="section-6.16"></a><p></p>
<h2><span class="Italics">Diflunisal</span></h2>
<p class="First">The concomitant administration of sulindac and diflunisal in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_9ea32ce5-0931-410f-bc37-e98411ab5cbc"></a><a name="section-6.17"></a><p></p>
<h2>Diuretics</h2>
<p class="First">Clinical studies, as well as post marketing observations, have shown that sulindac can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for signs of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (see <a href="#i4i_warnings_id_da2bbcf1-d1e9-4556-a9da-071e1d3445bf">WARNINGS </a>, <a href="#i4i_warnings_id_bff5d5d1-6e9a-4e1f-957a-c2d42393e6f4">Renal Effects</a>, as well as to assure diuretic efficacy.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_0eaf82e5-97b1-4f01-9fc0-b35f6edd0c2b"></a><a name="section-6.18"></a><p></p>
<h2><span class="Italics">DMSO</span></h2>
<p class="First">DMSO should not be used with sulindac. Concomitant administration has been reported to reduce the plasma levels of the active sulfide metabolite and potentially reduce efficacy. In addition, this combination has been reported to cause <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_7d9f61da-fe44-4282-a9f5-ea5eea8ebc2f"></a><a name="section-6.19"></a><p></p>
<h2><span class="Italics">Lithium</span></h2>
<p class="First">NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_9a114da0-aaec-40ee-8819-2444c780aeda"></a><a name="section-6.20"></a><p></p>
<h2><span class="Italics">Methotrexate</span></h2>
<p class="First">NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_0baf8e97-8ad8-4356-b9f6-90dad4716a07"></a><a name="section-6.21"></a><p></p>
<h2><span class="Italics">NSAIDs</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d2bf0c4e-437b-492a-811e-a9f95dcbb6bb"></a><a name="section-6.21.1"></a><p></p>
<h3><span class="Italics">The concomitant use of sulindac with other NSAIDs is not recommended due to the increased possibility of <span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">gastrointestinal toxicity</span>, with little or no increase in efficacy.</span></h3>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_585db266-db53-41ba-a406-fb1f341761d3"></a><a name="section-6.22"></a><p></p>
<h2><span class="Italics">Oral anticoagulants</span></h2>
<p class="First">Although sulindac and its sulfide metabolite are highly bound to protein, studies in which sulindac was given at a dose of 400 mg daily have shown no clinically significant interaction with oral anticoagulants. However, patients should be monitored carefully until it is certain that no change in their anticoagulant dosage is required. Special attention should be paid to patients taking higher doses than those recommended and to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or other metabolic defects that might increase sulindac blood levels. The effects of warfarin and NSAIDs on GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> are synergistic, such that users of both drugs together have a risk of serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> higher than users of either drug alone.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_6167cf44-4195-4cbb-9860-a5dbac1c644f"></a><a name="section-6.23"></a><p></p>
<h2><span class="Italics">Oral hypoglycemic agents</span></h2>
<p class="First">Although sulindac and its sulfide metabolite are highly bound to protein, studies in which sulindac was given at a dose of 400 mg daily, have shown no clinically significant interaction with oral hypoglycemic agents. However, patients should be monitored carefully until it is certain that no change in their hypoglycemic dosage is required. Special attention should be paid to patients taking higher doses than those recommended and to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or other metabolic defects that might increase sulindac blood levels.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_d85a958f-93bf-4c24-9cc2-aeb93e7d52a2"></a><a name="section-6.24"></a><p></p>
<h2><span class="Italics">Probenecid</span></h2>
<p class="First">Probenecid given concomitantly with sulindac had only a slight effect on plasma sulfide levels, while plasma levels of sulindac and sulfone were increased. Sulindac was shown to produce a modest reduction in the uricosuric action of probenecid, which probably is not significant under most circumstances.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_67e3e659-69ac-4f0a-b13d-df493939f9d2"></a><a name="section-6.25"></a><p></p>
<h2><span class="Italics">Propoxyphene hydrochloride</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8e1c3837-8f5f-4e89-a48e-a72925fef5c5"></a><a name="section-6.25.1"></a><p></p>
<h3><span class="Italics">Propoxyphene hydrochloride had no effect on the plasma levels of sulindac or its sulfide metabolite.</span></h3>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_c4722fc1-bcc4-42be-8552-542aaf29fe79"></a><a name="section-6.26"></a><p></p>
<h2>Pregnancy</h2>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_ff65f46f-3637-4fbf-94cf-fca77d020579"></a><a name="section-6.27"></a><p></p>
<h2>Teratogenic Effects. Pregnancy Category C.</h2>
<p class="First">Reproductive studies conducted in rats and rabbits have not demonstrated evidence of developmental abnormalities. However, animal reproduction studies are not always predictive of human response. There are no adequate and well-controlled studies in pregnant women. Sulindac should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_74ee202a-0ffa-4fc8-94c4-ade5f006ec2d"></a><a name="section-6.28"></a><p></p>
<h2>NonTeratogenic Effects</h2>
<p class="First">Because of the known effects of non-steroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during pregnancy (particularly late pregnancy) should be avoided.</p>
<p>The known effect of drugs of this class on the human fetus during the third trimester of pregnancy include: constriction of the ductus arteriosus prenatally, <span class="product-label-link" type="condition" conceptid="4006971" conceptname="Tricuspid valve regurgitation">tricuspid incompetence</span>, and <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>; non-closure of the ductus arteriosus postnatally which may be resistant to medical management; myocardial degenerative changes, platelet dysfunction with resultant <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, renal dysfunction or failure, <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>/dysgenesis which may result in prolonged or permanent <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> or perforation, and increased risk of <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span>.</p>
<p>In reproduction studies in the rat, a decrease in average fetal weight and an increase in numbers of dead pups were observed on the first day of the postpartum period at dosage levels of 20 and 40 mg/kg/day (2Â½ and 5 times the usual maximum daily dose in humans), although there was no adverse effect on the survival and growth during the remainder of the postpartum period. Sulindac prolongs the duration of gestation in rats, as do other compounds of this class. Visceral and skeletal malformations observed in low incidence among rabbits in some teratology studies did not occur at the same dosage levels in repeat studies, nor at a higher dosage level in the same species.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_b03ef96d-8b6e-430e-a62a-d2c5df393c53"></a><a name="section-6.29"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">In rat studies with NSAIDs, as with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia, delayed parturition, and decreased pup survival occurred. The effects of sulindac on labor and delivery in pregnant women are unknown.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_840b1325-0073-45c5-8564-4efc8ae675eb"></a><a name="section-6.30"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk; however, it is secreted in the milk of lactating rats. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from sulindac, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_4fda43e3-bb4d-47f3-8591-4ff2f6e45d81"></a><a name="section-6.31"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_f7fc5a44-85ef-45b4-8510-de304147deb5"></a><a name="section-6.32"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">As with any NSAID, caution should be exercised in treating the elderly (65 years and older) since advancing age appears to increase the possibility of adverse reactions. Elderly patients seem to tolerate ulceration or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> less well than other individuals and many spontaneous reports of fatal GI events are in this population (see <a href="#i4i_warnings_id_da2bbcf1-d1e9-4556-a9da-071e1d3445bf">WARNINGS </a> - <a href="#i4i_warnings_id_8d0c8416-06f8-44d7-85b5-71a598e004b4">Gastrointestinal Effects - Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation </a>). </p>
<p>Sulindac is known to be substantially excreted by the kidney and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function (See <a href="#i4i_warnings_id_da2bbcf1-d1e9-4556-a9da-071e1d3445bf">WARNINGS </a>, <a href="#i4i_warnings_id_bff5d5d1-6e9a-4e1f-957a-c2d42393e6f4">Renal Effects</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_86bd9b1b-ebbe-41c8-ade4-6a1d410dcabd"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions were reported in clinical trials or have been reported since the drug was marketed. The probability exists of a causal relationship between sulindac and these adverse reactions. The adverse reactions which have been observed in clinical trials encompass observations in 1,865 patients, including 232 observed for at least 48 weeks.</p>
<p><span class="Italics">Incidence Greater Than 1%</span></p>
<p><span class="Italics">Gastrointestinal</span></p>
<p>The most frequent types of adverse reactions occurring with sulindac are gastrointestinal; these include <span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">gastrointestinal pain</span> (10%), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>***, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>*** with or without <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>***, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>***, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> and <span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">gastrointestinal cramps</span>.</p>
<p><span class="Italics">Dermatologic</span></p>
<p><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>***, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p>
<p><span class="Italics">Central Nervous System</span></p>
<p><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>***, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>***, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>.</p>
<p><span class="Italics">Special Senses</span></p>
<p><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span>.</p>
<p><span class="Italics">Miscellaneous</span></p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> (see <span class="Bold"><a href="#i4i_warnings_id_da2bbcf1-d1e9-4556-a9da-071e1d3445bf">WARNINGS </a></span>).</p>
<p><span class="Italics">Incidence Less Than 1 in 100</span></p>
<p><span class="Italics">Gastrointestinal</span></p>
<p><span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">Gastritis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span> or <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic ulcer</span> and <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> have been reported. <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">GI perforation</span> and <span class="product-label-link" type="condition" conceptid="4044413" conceptname="Stenosis of intestine">intestinal strictures</span> (diaphragms) have been reported rarely.</p>
<p>Liver function abnormalities; <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, sometimes with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>; <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>; <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>.</p>
<p>There have been rare reports of sulindac metabolites in common bile duct âsludgeâ? and in biliary calculi in patients with symptoms of <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span> who underwent a cholecystectomy.</p>
<p><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> (see <span class="Bold"><a href="#i4i_precautions_id_57fd4ab8-65d0-4137-bf04-3cefd37bde03">PRECAUTIONS</a></span>).</p>
<p><span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">Ageusia</span>; <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>.</p>
<p><span class="Italics">Dermatologic</span></p>
<p><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>, sore or dry mucous membranes, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> have been reported.</p>
<p>___________________</p>
<p>***Incidence between 3% and 9%. Those reactions occurring in 1% to 3% of patients are not marked with an asterisk.</p>
<p><span class="Italics">Cardiovascular</span></p>
<p><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span>, especially in patients with marginal cardiac function; <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>; <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p><span class="Italics">Hematologic</span></p>
<p><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>; <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, including <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>; <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients on oral anticoagulants (see <span class="Bold"><a href="#i4i_precautions_id_57fd4ab8-65d0-4137-bf04-3cefd37bde03">PRECAUTIONS</a></span>).</p>
<div class="Section" data-sectionCode="34085-1">
<a name="i4i_controlled_substance_id_74fadebc-f8dc-4c87-a921-9aa2b8e85ff6"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold"><span class="Italics">Genitourinary</span></span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4055281" conceptname="Urine color abnormal">Urine discoloration</span>; <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>; <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>; <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>; <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>; <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>; interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>; <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>. </p>
<p><span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Renal calculi</span> containing sulindac metabolites have been observed rarely.</p>
<p><span class="Italics">Metabolic</span></p>
<p><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>.</p>
<p><span class="Italics">Musculoskeletal</span></p>
<p><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span>.</p>
<p><span class="Italics">Psychiatric</span></p>
<p><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>; <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">psychic disturbances</span> including acute <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>.</p>
<p><span class="Italics">Nervous System</span></p>
<p><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>; <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>; <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>; <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>; <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>; <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>; <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span> (especially in patients with <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> (SLE) and <span class="product-label-link" type="condition" conceptid="4134867" conceptname="Mixed collagen vascular disease">mixed connective tissue disease</span>, see <a href="#i4i_precautions_id_57fd4ab8-65d0-4137-bf04-3cefd37bde03">PRECAUTIONS</a>).</p>
<p><span class="Italics">Special Senses</span></p>
<p><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>; <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>; decreased hearing; metallic or bitter taste.</p>
<p><span class="Italics">Respiratory</span></p>
<p><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>; <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>; <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>; <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchial spasm</span>; <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">Hypersensitivity vasculitis</span>.</p>
<p>A potentially fatal apparent <span class="product-label-link" type="condition" conceptid="45765791" conceptname="Drug reaction with eosinophilia and systemic symptoms">hypersensitivity syndrome</span> has been reported. This syndrome may include constitutional symptoms (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>), cutaneous findings (<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other dermatologic reactions â see above), <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, involvement of major organs (changes in liver function including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> with or without <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>), and other less specific findings (<span class="product-label-link" type="condition" conceptid="316084" conceptname="Lymphadenitis">adenitis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>).</p>
<p><span class="Italics">Causal Relationship Unknown</span></p>
<p>A rare occurrence of fulminant <span class="product-label-link" type="condition" conceptid="133566" conceptname="Necrotizing fasciitis">necrotizing fasciitis</span>, particularly in association with Group A Î²-hemolytic streptococcus, has been described in persons treated with non-steroidal anti-inflammatory agents, sometimes with fatal outcome (see also <a href="#i4i_precautions_id_57fd4ab8-65d0-4137-bf04-3cefd37bde03">PRECAUTIONS</a>).</p>
<p>Other reactions have been reported in clinical trials or since the drug was marketed, but occurred under circumstances where a causal relationship could not be established. However, in these rarely reported events, that possibility cannot be excluded. Therefore, these observations are listed to serve as alerting information to physicians.</p>
<p><span class="Italics">Cardiovascular</span></p>
<p><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span>.</p>
<p><span class="Italics">Metabolic</span></p>
<p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>.</p>
<p><span class="Italics">Nervous System</span></p>
<p><span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">Neuritis</span>.</p>
<p><span class="Italics">Special Senses</span></p>
<p>Disturbances of the retina and its vasculature.</p>
<p><span class="Italics">Miscellaneous</span></p>
<p><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c69ebd05-7fad-4732-b0d7-d469e1788e45"></a><a name="section-8"></a><p></p>
<h1>MANAGEMENT OF OVERDOSAGE</h1>
<p class="First">Cases of overdosage have been reported and rarely, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have occurred. The following signs and symptoms may be observed following overdosage; <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, diminished urine output and hyportension.</p>
<p>In the event of overdosage, the stomach should be emptied by inducing <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or by gastric lavage, and the patient carefully observed and given symptomatic and supportive treatment.</p>
<p>Animal studies show that absorption is decreased by the prompt administration of activated charcoal and excretion is enhanced by alkalinization of the urine.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_53f5a12c-cc0b-4b7e-acff-128b74b93c3a"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <span class="Bold"><a href="#i4i_warnings_id_da2bbcf1-d1e9-4556-a9da-071e1d3445bf">WARNINGS </a></span>).</p>
<p>After observing the response to initial therapy with Sulindac Tablets USP, the dose and frequency should be adjusted to suit an individual patientâs needs.</p>
<p>Sulindac Tablets should be administered orally twice a day with food. The maximum dosage is 400 mg per day. Dosages above 400 mg per day are not recommended.</p>
<p>In <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>, <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, and <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span>, the recommended starting dosage is 150 mg twice a day. The dosage may be lowered or raised depending on the response.</p>
<p>A prompt response (within one week) can be expected in about one-half of patients with <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>, <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span>, and <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>. Others may require longer to respond.</p>
<p>In acute painful shoulder (acute subacromial <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span>/supraspinatus <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span>) and acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span>, the recommended dosage is 200 mg twice a day. After a satisfactory response has been achieved, the dosage may be reduced according to the response. In acute painful shoulder, therapy for 7-14 days is usually adequate. In acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span>, therapy for 7 days is usually adequate.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_83091908-c703-4169-90a1-1b74b1cb2998"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Sulindac Tablets USP, 150 mg are yellow, round tablets, bisected and debossed with âEâ? to the left of bisect and â10â? to the right of bisect on one side, and plain on the other side, available in:</p>
<p>Bottles of 100 (NDC 60429-171-01)</p>
<p>Bottles of 180 (NDC 60429-171-18)</p>
<p>Bottles of 500 (NDC 60429-171-05)</p>
<p>Sulindac Tablets USP, 200 mg are yellow, oval-shaped tablets, bisected and debossed with âEâ? to the left of bisect and â11â? to the right of bisect on one side, and plain on the other side, available in: </p>
<p>Bottles of 60 (NDC 60429-172-60)</p>
<p>Bottles of 100 (NDC 60429-172-01)</p>
<p>Bottles of 180 (NDC 60429-172-18)</p>
<p>Bottles of 500 (NDC 60429-172-05)</p>
<p><span class="Italics">Storage</span></p>
<p>Store in a well-closed container at 20Âº to 25ÂºC (68 to 77ÂºF) [see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="i4i_medguide_id_0dcbf841-0164-4a31-843e-2c4d606969b2"></a><a name="section-11"></a><p></p>
<h1>MEDICATION GUIDE FOR NON-STEROIDAL ANTIINFLAMMATORY DRUGS (NSAIDs)<span class="Underline"><br>(See the end of this Medication Guide for a list of prescription NSAID medicines)</span>
</h1>
<p class="First"><br><span class="Bold">What is the most important information I should know about medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<ul>
<li>with longer use of NSAID medicines</li>
<li>in people who have heart disease<br>
</li>
</ul>
<p><span class="Bold">NSAID medicines should never be used right before or after heart surgery called a âcoronary artery bypass graft (CABG).â?</span></p>
<p><span class="Bold">NSAID medicines can cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the stomach and intestines at any time during treatment.</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>: </span></p>
<ul>
<li>can happen without warning symptoms</li>
<li>may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></li>
</ul>
<p><span class="Bold">The chance of a person getting an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increases with: </span></p>
<ul>
<li>taking medicines called âcorticosteroidsâ? and âanticoagulantsâ?</li>
<li>longer use</li>
<li>smoking</li>
<li>drinking alcohol</li>
<li>older age</li>
<li>having poor health<br>
</li>
</ul>
<p><span class="Bold">NSAID medicines should only be used:</span></p>
<ul>
<li>exactly as prescribed</li>
<li>at the lowest dose possible for your treatment</li>
<li>for the shortest time needed<br>
</li>
</ul>
<p><span class="Bold">What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<p>NSAID medicines are used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and heat (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>) from medical conditions such as:</p>
<ul>
<li> different types of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span></li>
<li> <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">menstrual cramps</span> and other types of short-term <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span><br>
</li>
</ul>
<p><span class="Bold">Who should not take a Non-Steroidal Anti-Inflammatory Drug (NSAID)? Do not take an NSAID medicine:</span></p>
<ul>
<li>if you had an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> with aspirin or any other NSAID medicine</li>
<li>for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> right before or after heart bypass surgery<br>
</li>
</ul>
<p><span class="Bold">Tell your healthcare provider:</span></p>
<ul><li>about all of your medical conditions</li></ul>
<ul><li>about all of the medicines you take. NSAIDs and some other medicines can interact with each other and cause serious side effects. <span class="Bold">Keep a list of your medicines to show to your healthcare provider and pharmacist. </span>
</li></ul>
<ul>
<li>if you are pregnant. <span class="Bold">NSAID medicines should not be used by pregnant women late in their </span><span class="Bold">pregnancy.</span><br>
</li>
<li>if you are breastfeeding. <span class="Bold">Talk to your doctor.</span><br>
</li>
</ul>
<p>What are the possible side effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</p>
<a name="id_75c74262-c4ad-410e-875f-cb1880d77869"></a><table border="single" width="423.000">
<col width="61.7%">
<col width="38.3%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Rrule" align="justify" valign="top">
<span class="Bold">Serious side effects include:</span><p class="First">Â </p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>high blood pressure</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> from body <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>)</li>
<li>kidney problems including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span></li>
</ul>
<ul><li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestine</li></ul>
<ul><li>low red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>)</li></ul>
<ul><li>life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span></li></ul>
<ul><li>life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></li></ul>
<ul><li>liver problems including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span></li></ul>
<ul><li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks in people who have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li></ul>
</td>
<td class="Botrule" align="justify" valign="top">
<p class="First"><span class="Bold">Other side effects include:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>gas</li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
</ul>
</td>
</tr></tbody>
</table>
<p><span class="Bold">Get emergency help right away if you have any of the following symptoms:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing </li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> </li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in one part or side of your body</li>
<li><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat<br>
</li>
</ul>
<p><span class="Bold">Stop your NSAID medicine and call your healthcare provider right away if you have any of the following symptoms:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>more tired or weaker than usual</li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li>your skin or eyes look yellow</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li>flu-like symptoms</li>
<li>vomit blood</li>
<li>there is blood in your bowel movement<p class="First">or it is black and sticky like tar<br></p>
</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> with <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the arms and legs, hands and feet<p class="First"><br>These are not all the side effects with NSAID medicines. Talk to your healthcare provider or pharmacist for more information about NSAID medicines.</p>
<p><br><span class="Bold">Other information about Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)</span></p>
<p></p>
</li>
<li>Aspirin is an NSAID medicine but it does not increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. Aspirin can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the brain, stomach, and intestines. Aspirin can also cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestines.<br>
</li>
<li>Some of these NSAID medicines are sold in lower doses without a prescription (over-the-counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.</li>
</ul>
<a name="id_b3316c59-ccc2-4a97-b531-ec7e092a2d5d"></a><table border="single" width="536.000">
<col width="20.1%">
<col width="79.9%">
<tbody class="Headless">
<tr class="First"><td class="Botrule" align="center" colspan="2" valign="middle">NSAID medicines that need a prescription</td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Generic Name</span></td>
<td class="Botrule" align="left" valign="top"><span class="Bold">Tradename</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Celecoxib</td>
<td class="Botrule" align="left" valign="top">Celebrex</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Diclofenac</td>
<td class="Botrule" align="left" valign="top">Cataflam, Voltaren, Arthrotec (combined with misoprostol)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Diflunisal</td>
<td class="Botrule" align="left" valign="top">Dolobid</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Etodolac</td>
<td class="Botrule" align="left" valign="top">Lodine, Lodine XL</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Fenoprofen</td>
<td class="Botrule" align="left" valign="top">Nalfon, Nalfon 200</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Flurbiprofen</td>
<td class="Botrule" align="left" valign="top">Ansaid</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Ibuprofen</td>
<td class="Botrule" align="left" valign="top">Motrin, Tab-Profen, Vicoprofen<a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=18958">*</a> (combined with hydrocodone), Combunox (combined with oxycodone)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Indomethacin</td>
<td class="Botrule" align="left" valign="top">Indocin, Indocin SR, Indo-Lemmon, Indomethegan</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Ketoprofen</td>
<td class="Botrule" align="left" valign="top">Oruvail</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Ketorolac</td>
<td class="Botrule" align="left" valign="top">Toradol</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Mefenamic Acid</td>
<td class="Botrule" align="left" valign="top">Ponstel</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Meloxicam</td>
<td class="Botrule" align="left" valign="top">Mobic</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Nabumetone</td>
<td class="Botrule" align="left" valign="top">Relafen</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Naproxen</td>
<td class="Botrule" align="left" valign="top">Naprosyn, Anaprox, Anaprox DS, EC-Naprosyn, Naprelan, Naprapac (copackaged with lansoprazole)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Oxaprozin</td>
<td class="Botrule" align="left" valign="top">Daypro</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Piroxicam</td>
<td class="Botrule" align="left" valign="top">Feldene</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Sulindac</td>
<td class="Botrule" align="left" valign="top">Clinoril</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Tolmetin</td>
<td class="Botrule" align="left" valign="top">Tolectin, Tolectin DS, Tolectin 600</td>
</tr>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="2" valign="top">
<p class="First"><a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=18958">*</a></p>Vicoprofen contains the same dose of ibuprofen as over-the-counter (OTC) NSAIDs, and is usually used for less than 10 days to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The OTC NSAID label warns that long term continuous use may increase the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. </td></tr>
</tbody>
</table>
<p><span class="Bold"><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></span></p>
<p><span class="Italics">This Medication Guide has been approved by the U.S. Food and Drug Administration</span></p>
<dl>
<dt>Â </dt>
<dd>Manufactured By: <span class="Bold">Epic Pharma, LLC </span>Laurelton, NY 11413</dd>
<dt>Â </dt>
<dd>Marketed/Packaged by: <span class="Bold">GSMS Inc. </span>Camarillo, CA 93012</dd>
<dt>Â </dt>
<dd>Revised 06/10</dd>
<dt>Â </dt>
<dd>MF018REV0610</dd>
<dt>Â </dt>
<dd>OE1000</dd>
</dl>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_fe1f1f0c-5500-406a-8b27-d43c9049cfc8"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 150 mg</h1>
<div class="Figure"><img alt="Label Graphic - 150 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=19dde540-3d29-4db4-9570-6ca15f09e0fe&amp;name=19dde540-3d29-4db4-9570-6ca15f09e0fe-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_2f0cea12-6c6f-4203-b54a-67571fb2f3e4"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 200 mg</h1>
<div class="Figure"><img alt="Label Graphic - 200 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=19dde540-3d29-4db4-9570-6ca15f09e0fe&amp;name=19dde540-3d29-4db4-9570-6ca15f09e0fe-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SULINDACÂ 		
					</strong><br><span class="contentTableReg">sulindac tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60429-171(NDC:42806-018)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SULINDAC</strong> (SULINDAC) </td>
<td class="formItem">SULINDAC</td>
<td class="formItem">150Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K29/32</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">E10</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60429-171-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:60429-171-18</td>
<td class="formItem">180  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:60429-171-05</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA072710</td>
<td class="formItem">01/25/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SULINDACÂ 		
					</strong><br><span class="contentTableReg">sulindac tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60429-172(NDC:42806-011)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SULINDAC</strong> (SULINDAC) </td>
<td class="formItem">SULINDAC</td>
<td class="formItem">200Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K30</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">E11</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60429-172-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:60429-172-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:60429-172-18</td>
<td class="formItem">180  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:60429-172-05</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA072711</td>
<td class="formItem">01/25/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Golden State Medical Supply, Inc.
							(603184490)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Golden State Medical Supply, Inc.</td>
<td class="formItem"></td>
<td class="formItem">603184490</td>
<td class="formItem">REPACK(60429-171, 60429-172), RELABEL(60429-171, 60429-172)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>19dde540-3d29-4db4-9570-6ca15f09e0fe</div>
<div>Set id: 19dde540-3d29-4db4-9570-6ca15f09e0fe</div>
<div>Version: 1</div>
<div>Effective Time: 20110701</div>
</div>
</div>Â <div class="DistributorName">Golden State Medical Supply, Inc.</div></p>
</body></html>
